학술논문
Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trial
Document Type
Article
Author
Davies, A.; Cummin, T.E.; Johnson, P.W.M.; Maishman, T.; Caddy, J.; Stanton, L.; Griffiths, G.; Barrans, S.; Tooze, R.; Burton, C.; Mamot, C.; Novak, U.; Kazmi-Stokes, S.; McMillan, A.; Fields, P.; Pocock, C.; Collins, G.P.; Stephens, R.; Cucco, F.; Clipson, A.; Du, M.-Q.; Sha, C.; Westhead, D.R.; Care, M.A.
Source
In: The Lancet Oncology . (The Lancet Oncology, May 2019, 20(5):649-662)
Subject
Language
English
ISSN
14745488
14702045
14702045